Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.
- Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.
- In the Third Calendar Quarter 2022, Benitec submitted responses to the Central Ethics Committee (CEC) related to minor non-clinical queries.
- BB-301 Phase 1b/2a Regulatory Updates:
Investigational New Drug (IND) and Clinical Trial Application (CTA) filings are anticipated in the First Calendar Quarter 2023. - Total Revenues for the quarter ended September 30, 2022, were $0 compared to $0 for the quarter ended September 30, 2021.